Recent research in the New England Journal of Medicine highlights significant advances in colorectal cancer (CRC) screening. Novigenix AI leads this innovation with our unique approach that combines liquid biopsy, AI, and RNA analysis, promising a transformative impact on early cancer detection. Colorectal cancer is a major global health concern, projected to rise by
04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix IA, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients.
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix AI, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is
LAUSANNE, SWITZERLAND – Novigenix AI, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s
New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients LAUSANNE, SWITZERLAND - September 9th, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of
New precision solutions may be accessible on Philips IntelliSpace Precision Medicine Platform LAUSANNE, SWITZERLAND - March 8, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to
Publication in Cancers Journal Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 LAUSANNE, SWITZERLAND - September 23rd, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced release of the article: “Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell